1087-0156

View prefix report (10.1038)

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 118 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact118 DOIs
2

Attach ORCID iDs across 118 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact118 DOIs
3

Deposit reference lists for 87 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact87 DOIs

DOIs for this ISSN

Showing the top 5 of 118 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Targeted mutagenesis in zebrafish (10.1038/nbt0608-650)
Abstract ORCID
74.57 30
2 Threat to global GM soybean access as patent nears expiry (10.1038/nbt0113-10c)
Abstract References ORCID
63.38 6
3 High throughput screening on a low budget (10.1038/nbt0496-513)
Abstract References ORCID
63.38 6
4 Going with the flow (10.1038/nbt0602-527)
Abstract References ORCID
58.36 5
5 Biotechnology in the Food Industry (10.1038/nbt0893-895)
Abstract ORCID
55.70 12
6 The sweet allure of XNA (10.1038/nbt.2298)
Abstract ORCID
50.00 9
7 Cell Pathways to file NDA (10.1038/11619)
Abstract References ORCID
45.15 3
8 Who's Who in European Antibiotech (10.1038/nbt0193-44)
Abstract References ORCID
45.15 3
9 Microbes to Clean Up Marble? (10.1038/nbt0984-757)
Abstract References ORCID
45.15 3
10 Canadian farmer found guilty of Monsanto canola patent infri… (10.1038/88013)
Abstract ORCID
42.25 6
11 RNA sequencing in situ (10.1038/nbt.2921)
Abstract ORCID
38.91 5
12 Total target cash compensation shows a healthy increase at p… (10.1038/nbt.3166)
Abstract ORCID
38.91 5
13 Genetic variation and alternative splicing (10.1038/nbt.3195)
Abstract ORCID
38.91 5
14 A window on the dynamics of biological switches (10.1038/nbt0205-183)
Abstract ORCID
38.91 5
15 Technical Reports (10.1038/83622)
Abstract References ORCID
35.78 2
16 Nutraceuticals tread business tightrope in Europe (10.1038/nbt0402-322b)
Abstract References ORCID
35.78 2
17 Environmental Cancer and Biotechnology (10.1038/nbt0688-675)
Abstract References ORCID
35.78 2
18 Receptor Screens Detect Bioactivity (10.1038/nbt0891-694a)
Abstract References ORCID
35.78 2
19 Ultra-precision medicine (10.1038/s41587-021-00967-8)
Abstract References ORCID
35.78 2
20 Surveying the best in translation (10.1038/nbt.2887)
Abstract ORCID
34.95 4
21 Affymax poised to challenge Amgen (10.1038/nbt0512-377)
Abstract ORCID
34.95 4
22 Space Bioprocessing (10.1038/nbt0985-786)
Abstract ORCID
34.95 4
23 European biotechnology turns East (10.1038/8606)
Abstract ORCID
30.10 3
24 Gilead bets big on Nimbus' fatty liver disease drug (10.1038/nbt0616-575)
Abstract ORCID
30.10 3
25 California votes for embryonic stem cell research (10.1038/nbt1204-1485)
Abstract ORCID
30.10 3
26 New tools for an old workhorse (10.1038/82339)
Abstract ORCID
23.86 2
27 Discontent with consent (10.1038/nbt.2270)
Abstract ORCID
23.86 2
28 Protecting rights to early-stage technology (10.1038/nbt0603-701)
Abstract ORCID
23.86 2
29 Gunvalson decision sends shockwaves through industry (10.1038/nbt1108-1201)
Abstract ORCID
23.86 2
30 Roberts Rules of Disorder (10.1038/nbt0391-209)
Abstract References ORCID
22.58 1
31 UK bidding war amidst merger mania (10.1038/nbt0403-343)
Abstract References ORCID
22.58 1
32 Announcements (10.1038/nbt0585-485)
Abstract References ORCID
22.58 1
33 Fermentation Special Report (10.1038/nbt0588-505)
Abstract References ORCID
22.58 1
34 Bone Repair: Collagen Corp. Isolates Cartilage Inducers (10.1038/nbt0685-507)
Abstract References ORCID
22.58 1
35 Making the Transition to Applied Technology (10.1038/nbt0890-714)
Abstract References ORCID
22.58 1
36 People (10.1038/nbt0905-1186)
Abstract References ORCID
22.58 1
37 Growing the bioscience career pipeline (10.1038/nbt0908-1047)
Abstract References ORCID
22.58 1
38 The Fractal Geometry of the Heart (10.1038/nbt1289-1219)
Abstract References ORCID
22.58 1
39 Reigning in regulatory T-cell function (10.1038/nbt.3285)
Abstract ORCID
15.05 1
40 What the roll out of EU data legislation means for you (10.1038/nbt.3928)
Abstract ORCID
15.05 1
41 Amgen swallows Micromet to BiTE into ALL market (10.1038/nbt0412-300c)
Abstract ORCID
15.05 1
42 Rediscovering plant-based drugs (10.1038/nbt0803-843b)
Abstract ORCID
15.05 1
43 The Biology of the Interferon System (10.1038/nbt0883-480)
Abstract ORCID
15.05 1
44 Industry wary of NIH consultancy moratorium (10.1038/nbt1104-1331)
Abstract ORCID
15.05 1
45 Research Collaborations (10.1038/15008)
Abstract References ORCID
0.00 0
46 Recent antibody-related patents (10.1038/7052)
Abstract References ORCID
0.00 0
47 Alternative antisense (10.1038/71830)
Abstract References ORCID
0.00 0
48 Research collaborations (10.1038/72003)
Abstract References ORCID
0.00 0
49 Finance boom in 4Q, 1999 (10.1038/72491)
Abstract References ORCID
0.00 0
50 Biotech companies adapt to big pharma mergers (10.1038/75337)
Abstract References ORCID
0.00 0